Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

Stargardt Disease Clinical Trial

— STARLIGHT  

Official title:

A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05417126
• Other study ID #: NTXMCO-004
• Status: Completed
• Phase: Phase 2
• Start date: July 5, 2022
• Est. completion date: September 28, 2023

Study information

• Verified date: November 2023
• Source: Nanoscope Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease

Description:

This multicenter open label study will evaluate single dose level of vMCO-010 in up to 6 subjects with Stargardt's Disease. Subjects with documented clinical diagnosis of Stargardt disease (classic fleck phenotype and/or well-demarcated sub-foveal area of significantly reduced autofluorescence as imaged by FAF), or genetic diagnosis with pathogenic variants in ABCA4, ELOVL4, or PROM 1. All subjects will continue to be assessed for 48 weeks following treatment with vMCO-010.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: September 28, 2023
• Est. primary completion date: August 2, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

1. =16 years of age

2. Able to comprehend and give informed consent.

3. Able to comply with testing and all protocol tests.

4. Documented clinical diagnosis of Stargardt disease (classic fleck phenotype and/or well-demarcated sub-foveal area of significantly reduced autofluorescence as imaged by FAF), or genetic diagnosis with pathogenic variants in ABCA4, ELOVL4, or PROM1

5. In the study eye: ETDRS BCVA in range of 1.3 logMAR (Approximate Snellen equivalent:

20/400) to 1.9 logMAR (Snellen equivalent: 20/1600), and ETDRS BCVA no better than 20/200 in the fellow eye.

6. Presence of retinal inner nuclear and nerve fiber layers on optical coherence tomography (OCT) testing in the study eye at screening

Exclusion Criteria:

1. Presence of any concurrent ocular disease that would affect study outcomes (e.g., severe cataracts; subjects can be enrolled 3 months after successful cataract surgery).

2. Received any of the following treatments: gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips (such as ARGUS-II) or sub-retinal injections.

3. Has taken non-approved items (supplement containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) over the past 30 days

4. Participation in an interventional study of a vitamin A derivative = 3 months prior to screening

5. Presence of significant cardiovascular or cerebrovascular disease, including stroke within 12 months of entry.

6. Resting heart rate outside specified limits upon repeated measurement.

7. History of uncontrolled diabetes, hepatitis, pancreatitis, cirrhosis, liver failure, uncontrolled thyroid disease or hypervitaminosis A.

8. Any intraocular surgery or thermal laser within 3 months of trial entry or any prior thermal laser in the macular region.

9. Any major surgical procedure within one month of trial entry or anticipated during the trial.

10. Clinically significant abnormal lab results at screening

11. Known serious allergies to the fluorescein dye used in angiography or intraocular pressure measurement, povidone iodine, or to the components of the vMCO-010 formulation

12. In the Investigator's opinion, any severe acute or chronic medical condition, psychiatric condition, physical examination finding or laboratory abnormality

13. Pre-existing conditions in the study eye such as glaucoma, diseases affecting the optic nerve causing significant visual field loss, history of uveitis, corneal or lenticular opacities).

14. Presence of any complicating systemic diseases such as malignancies whose treatment could affect central nervous system function..

15. Subjects who are positive for syphilis, hepatitis B, C, and human immunodeficiency virus (HIV) will be excluded..

16. Presence of narrow iridocorneal angles contraindicating pupillary dilation in the study eye.

17. Presence of disorders of the ocular media in the study eye which could interfere with visual acuity and other ocular assessments, including OCT, during the study period.

18. Presence of macular hole in the study eye, evident by ophthalmoscopy and/or by OCT examinations

19. Current evidence of retinal detachment in the study eye assessed by the Investigator that significantly affects central vision.

20. Current use of hydroxychloroquine, chloroquine, or any related retina-toxic compounds.

21. Active ocular inflammation or recurrent history of idiopathic or autoimmune associated uveitis.

Related Conditions & MeSH terms

• Macular Degeneration
• Stargardt Disease

Intervention

Biological:
• Gene Therapy-vMCO-010
The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Locations

Country	Name	City	State
United States	Nanoscope Clinical Site	McAllen	Texas
United States	Nanoscope Clinical Site	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Nanoscope Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Type, severity, and incidence of ocular and systemic adverse events (AEs)	Type, severity, and incidence of ocular and systemic adverse events (AEs), specifically those related to intravitreal injection of vMCO-010	48 weeks
Secondary	Effect of vMCO-010 as assessed by visual acuity	Change from baseline in BCVA at Weeks 12, 24, 48 in the study eye and the fellow eye	48 weeks
Secondary	Effect of vMCO-010 on Light-guided Mobility	Change from baseline in Multi-Luminance Mobility Test at weeks 12, 24, 48 in the study eye and the fellow eye	48 Weeks
Secondary	Effect of vMCO-010 on determination of shape	Change from baseline in accuracy in determination of shape using Low Vision Multi-Parameter Test (LVMPT) at weeks 12, 24, 48 in the study eye and the fellow eye	48 Weeks
Secondary	Effect of vMCO-010 on determination of optical flow	Change from baseline in accuracy in determination of optical flow using the LVMPT at weeks 12, 24 and 48 in the study eye and the fellow eye	48 Weeks